Eduardo Dunayevich

Summary

Publications

  1. ncbi request reprint The cost of treating anxiety: the medical and demographic correlates that impact total medical costs
    Martin D Marciniak
    Lilly Research Laboratories, Indianapolis, IN, USA
    Depress Anxiety 21:178-84. 2005
  2. ncbi request reprint Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder
    Eduardo Dunayevich
    Orexigen Therapeutics, San Diego, CA 92130, USA
    Neuropsychopharmacology 33:1603-10. 2008
  3. ncbi request reprint Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder
    Eduardo Dunayevich
    Outcomes Research, Eli Lilly and Co, Indianapolis, IN, USA
    J Clin Psychiatry 68:1163-71. 2007
  4. ncbi request reprint Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes
    Eduardo Dunayevich
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Schizophr Res 86:300-8. 2006
  5. doi request reprint Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach
    Melissa Spann
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Psychiatr Res 43:561-7. 2009
  6. ncbi request reprint All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis
    Charles M Beasley
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 27:252-8. 2007
  7. ncbi request reprint A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia
    Gopalan Sethuraman
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 1730, Indianapolis, IN 46285, USA
    Schizophr Res 79:337-40. 2005
  8. ncbi request reprint Medical and productivity costs of anxiety disorders: case control study
    Martin Marciniak
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Depress Anxiety 19:112-20. 2004
  9. ncbi request reprint Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial
    James Hartford
    Community Research, Cincinnati, Ohio 45227, USA
    Int Clin Psychopharmacol 22:167-74. 2007
  10. ncbi request reprint Response to Kujawa et al. letter-to-the-editor
    Gopalan Sethuraman
    Schizophr Res 84:172-3. 2006

Collaborators

Detail Information

Publications11

  1. ncbi request reprint The cost of treating anxiety: the medical and demographic correlates that impact total medical costs
    Martin D Marciniak
    Lilly Research Laboratories, Indianapolis, IN, USA
    Depress Anxiety 21:178-84. 2005
    ....
  2. ncbi request reprint Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder
    Eduardo Dunayevich
    Orexigen Therapeutics, San Diego, CA 92130, USA
    Neuropsychopharmacology 33:1603-10. 2008
    ..Additional studies will be needed to further assess the toxicological and clinical profile of LY354740/LY544344...
  3. ncbi request reprint Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder
    Eduardo Dunayevich
    Outcomes Research, Eli Lilly and Co, Indianapolis, IN, USA
    J Clin Psychiatry 68:1163-71. 2007
    ..This study examines whether longer time to all-cause medication discontinuation is also linked to better functional outcomes...
  4. ncbi request reprint Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes
    Eduardo Dunayevich
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Schizophr Res 86:300-8. 2006
    ....
  5. doi request reprint Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach
    Melissa Spann
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Psychiatr Res 43:561-7. 2009
    ..Sample size was reduced from 311 to 156 patients, thereby decreasing the number of patients exposed to placebo from 54 to 30 and the number exposed to the active control with a known side effect from 126 to 60...
  6. ncbi request reprint All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis
    Charles M Beasley
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 27:252-8. 2007
    ..This integrated analysis compared the likelihood of discontinuation from olanzapine treatment versus other antipsychotics among patients with schizophrenia...
  7. ncbi request reprint A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia
    Gopalan Sethuraman
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 1730, Indianapolis, IN 46285, USA
    Schizophr Res 79:337-40. 2005
    ..Available studies suggest comparable efficacy of olanzapine and risperidone for the treatment of schizophrenia over the short term...
  8. ncbi request reprint Medical and productivity costs of anxiety disorders: case control study
    Martin Marciniak
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Depress Anxiety 19:112-20. 2004
    ..Results indicate that anxiety disorders are associated with significant medical and productivity costs...
  9. ncbi request reprint Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial
    James Hartford
    Community Research, Cincinnati, Ohio 45227, USA
    Int Clin Psychopharmacol 22:167-74. 2007
    ..9%, P=0.04), but not in the duloxetine group (19.4%, P=0.448) compared with placebo (15.8%). Duloxetine 60-120 mg/day and venlafaxine XR 75-225 mg/day were each efficacious treatments for patients with generalized anxiety disorder...
  10. ncbi request reprint Response to Kujawa et al. letter-to-the-editor
    Gopalan Sethuraman
    Schizophr Res 84:172-3. 2006
  11. ncbi request reprint Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics
    James L Karagianis
    J Clin Psychiatry 66:137; author reply 138. 2005